AF
EPZM

Amalgamated Financial’s Epizyme, Inc EPZM Stock Holding History

Amalgamated Financial’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$30K Buy
+26,516
New +$43.2K ﹤0.01% 2632

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amalgamated Financial's EPZM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Epizyme, Inc (EPZM) in Q1 2022: 26,516 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #2632 among its holdings.

120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Amalgamated Financial held 26,516 shares of Epizyme, Inc worth $30K as of Q1 2022.
  • Epizyme, Inc was a new Amalgamated Financial position in Q1 2022.
  • Epizyme, Inc made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2632 holding.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.